Royalty rateI'm not sure why you and other posters think that a...

Royalty rate

I'm not sure why you and other posters think that a 10% royalty is "cheap" - obs haven't done much research on the topic or been around bio/drug development much. With all costs being on the production company, not us the developer.

"Royalty rates can range from single-digit percentages to more substantial percentages, depending on the circumstances. In some cases, royalty rates can exceed 10%"

"On average, royalty rates for drugs typically range from 5% to 15% of net sales or profits generated from the licensed drug"

Some random examples:

Blockbuster Drugs: Some highly successful drugs, known as blockbuster drugs, have commanded significant royalty rates. For example, it has been reported that Merck & Co. paid a 25% royalty rate to Harvard University for the HIV medication efavirenz (brand name Sustiva) in the late 1990s.

Specialty Drugs: Specialty drugs often target niche markets and treat rare diseases, commanding higher royalty rates. In one reported case, BioMarin Pharmaceuticals paid a royalty rate of approximately 15% to the University of California for the drug Kuvan, which is used to treat a rare genetic disorder called phenylketonuria (PKU).

Biologic Therapies: Biologic therapies, which are complex and often derived from living organisms, can have higher royalty rates. For instance, Sanofi is reported to pay a royalty rate of approximately 8% to Regeneron Pharmaceuticals for their jointly developed drug Dupixent, used in the treatment of various allergic conditions.

Early-Stage Licensing: In early stages of drug development, royalty rates can be lower. For instance, a study published in the journal Nature Biotechnology found that the average royalty rate for early-stage licensing deals in the biotech sector was around 3.4%.


RX7

Pending RX5 so that we can make informed next-step decisions. This is waiting on the RX5 phase 3 clinical trial results, this is because once the results are out RX7 is able to leverage it already as part of its body of evidence, this means that RX7 is able to skip a few stages and be fast-tracked, alongside likely needing smaller /shorter cohort sizes for its clinical trials.impeding cap raise - phase 3 results around the cornergetting out now is bold move but that is bio for you either in it to win it or jump out as bio is risky, unless the company decides to do one last "place your bets" before results are out, the cap raise hopefully will be after the great success of our phase 3 results, these phase 3 results resulting in EMD as the leading company on its clinical trial path and potentially the first to receive TGA approval for schedule 3

This achievement would also allow EMD to proceed to the FDA with RX7, and there is a chance that it could become the first company since GW Pharma to obtain FDA approval.

Considering the progress of EMD's pipeline, a valuation exceeding $1 billion seems reasonable, as we have seen other companies reach this level with less advancement. It's important to note that EMD is the only company being closely monitored by Jazz Phama (bought GW phamas product for 7Billion - and this was for a rare/limited indication not a massive wide one like we are targeting), They already have commercial agreements with Australias leading phama distribution company, positioning them for success in the market.We are also extremely unique in that our formulation itself due to it being synthetic is able to be patented protected (unlike jazz/gw's product which is not - anyone can replicate so long as they do the work), this will also add a premium to any takeover.